Imaging is widely used for diagnosis and monitoring of neurological diseases. CT scans are routinely acquired in emergency units in patients with traumatic injuries or stroke. PET imaging has gained a strong foothold in oncology. MRI has become the standard of practice for the diagnosis, follow-up and management of numerous neurological and psychiatric conditions. All of these imaging techniques have in common that, in clinical practice, the images need to be interpreted visually by trained specialists, who are responsible for initial diagnosis or for interpretation of follow-up examinations. Within the scientific literature there is increasing emphasis on the use of quantitative medical imaging biomarkers, i.e. relevant numerical values that can be extracted from 2D or 3D medical image data sets, using advanced image processing techniques. Many imaging biomarkers, such as volumetric assessment of brain structures, have been shown to have excellent sensitivity and specificity for diagnosis or prognosis of various neurological diseases. In this chapter, we shall focus on the development of relevant MR imaging biomarkers for patients with multiple sclerosis (MS). However, several of the techniques described below can be generalised to other neurological conditions.
|Title of host publication||Imaging Biomarkers|
|Subtitle of host publication||Development and Clinical Integration|
|Editors||Luis Martí-Bonmati, Angel Alberich-Bayarri|
|Place of Publication||Switzerland|
|Publisher||Springer International Publishing AG|
|Number of pages||12|
|Publication status||Published - 1 Jan 2016|